Not available
Quote | Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA)
Last: | $13.56 |
---|---|
Change Percent: | 2.34% |
Open: | $13.31 |
Close: | $13.25 |
High: | $13.68 |
Low: | $13.31 |
Volume: | 2,389,386 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA)
2024-04-24 07:15:00 ET Summary Sound Shore Fund, Inc. is registered as a diversified, open-end management investment company. The investment objective of the Fund is growth of capital. The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10%, respecti...
2024-04-22 10:55:53 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...
Message Board Posts | Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading | JLS | investorshub | 05/08/2023 9:55:40 PM |
$TEVA The trading | Zilla | investorshub | 05/08/2023 8:56:28 PM |
and the shorts continue | Tigerbalsam | investorshub | 05/08/2023 3:10:48 AM |
Time for a bounce? | JLS | investorshub | 05/06/2023 5:42:43 PM |
$TEVA good read | WovenO2 | investorshub | 05/06/2023 3:13:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
The U.S. Supreme Court has reportedly chosen not to review Vanda Pharmaceuticals Inc’s (NASDAQ:VNDA) attempt to revive patents...
2024-04-19 05:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnso...